TY - JOUR
T1 - Ru-106 plaque radiotherapy for vasoproliferative tumors of retina
T2 - a 15-year single-center experience
AU - Abolfathzadeh, Navid
AU - Naseripour, Masood
AU - Jaberi, Ramin
AU - Azma, Zohreh
AU - Alemzadeh, Sayyed Amirpooya
AU - Arbab, Mona
AU - Sedaghat, Ahad
N1 - Funding Information:
This study is supported by the Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Publisher Copyright:
© 2020, Springer Nature B.V.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Purpose: This study evaluates the outcomes of ruthenium-106 (Ru-106) plaque brachytherapy for vasoproliferative tumors (VPTs) of the ocular fundus in a single referral ocular oncology center. Methods: The clinical charts of all patients diagnosed with VPT who underwent plaque radiotherapy from 2002 to 2017 were reviewed. Clinical features, types of treatment, outcomes and complications were evaluated. Results: Of 46 patients with VPT diagnosis in our ocular oncology clinic, 25 (54.34%) cases were treated with Ru-106 plaque brachytherapy. Eleven patients (44%) were male, and the mean age at the time of diagnosis was 40.92 ± 13.11 years. The mean follow-up time was 47.56 ± 36.87 months. Inferotemporal quadrant was the most common site of the tumor (64.00%). The mean delivered apex and scleral dose was 101.56 ± 6.51 and 412.26 ± 113.66 Gray (Gy), respectively. Initial tumor length, width and thickness were 10.26 ± 3.42, 8.05 ± 2.83 and 4.27 ± 1.10 mm, respectively. The mean tumor thickness decreased to 2.60 ± 0.63 mm, postoperatively. Complete resolution of subretinal fluid around the tumor was achieved in 81.80% of cases. Visual acuity was more than 20/400 in 64% of patients before treatment and 60% of patients at last follow-up. Conclusion: Our study showed that Ru-106 plaque radiotherapy is an effective and safe method of treatment in VPTs.
AB - Purpose: This study evaluates the outcomes of ruthenium-106 (Ru-106) plaque brachytherapy for vasoproliferative tumors (VPTs) of the ocular fundus in a single referral ocular oncology center. Methods: The clinical charts of all patients diagnosed with VPT who underwent plaque radiotherapy from 2002 to 2017 were reviewed. Clinical features, types of treatment, outcomes and complications were evaluated. Results: Of 46 patients with VPT diagnosis in our ocular oncology clinic, 25 (54.34%) cases were treated with Ru-106 plaque brachytherapy. Eleven patients (44%) were male, and the mean age at the time of diagnosis was 40.92 ± 13.11 years. The mean follow-up time was 47.56 ± 36.87 months. Inferotemporal quadrant was the most common site of the tumor (64.00%). The mean delivered apex and scleral dose was 101.56 ± 6.51 and 412.26 ± 113.66 Gray (Gy), respectively. Initial tumor length, width and thickness were 10.26 ± 3.42, 8.05 ± 2.83 and 4.27 ± 1.10 mm, respectively. The mean tumor thickness decreased to 2.60 ± 0.63 mm, postoperatively. Complete resolution of subretinal fluid around the tumor was achieved in 81.80% of cases. Visual acuity was more than 20/400 in 64% of patients before treatment and 60% of patients at last follow-up. Conclusion: Our study showed that Ru-106 plaque radiotherapy is an effective and safe method of treatment in VPTs.
KW - Plaque radiotherapy
KW - Primary
KW - Retina
KW - Ru-106
KW - Secondary
KW - Vasoproliferative tumor
UR - http://www.scopus.com/inward/record.url?scp=85085095032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085095032&partnerID=8YFLogxK
U2 - 10.1007/s10792-020-01386-5
DO - 10.1007/s10792-020-01386-5
M3 - Article
C2 - 32361860
AN - SCOPUS:85085095032
SN - 0165-5701
VL - 40
SP - 2095
EP - 2102
JO - International Ophthalmology
JF - International Ophthalmology
IS - 8
ER -